| Company Name: | ResMed Inc | | | Ticker Symbol: | RMD | | CIK Number: | 0000943819 | | WWW Address: | http://www.resmed.com |
| CEO: | Mr. Michael J. (Mike) Farrell | | No. of Employees: | 6,080 |
| Common Issue Type: | CS | | Business Description: | ResMed Inc. is a developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders.
|
| | | Industry Information: | HEALTH SERVICES - Medical Appliances & Equipment [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 73.07 |  0.28 | - | - | 72.82 | 73.26 | 72.49 | 529536 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 10,391.2 | 142.2 | 0.00 | 2.42 | 1.40 | 30.0 | 1.8 | 79.63 - 56.59 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 73.08 | $ | | PE Ratio - LTM | 30.0 | |
| Market Capitalisation | 10,391.2 | mil |
| Latest Shares Outstanding | 142.2 | mil |
| Earnings pS (EPS) | 2.42 | $ |
| Dividend pS (DPS) | 1.40 | ¢ |
| Dividend Yield | 1.8 | % |
| Dividend Payout Ratio | 1 | % |
| Revenue per Employee | 339,924 | $ |
| Effective Tax Rate | 0.2 | % |
| Float | 139.4 | mil |
| Float as % of Shares Outstanding | 1.0 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 0.30 | % |
| Research & Devlopment (R&D) as % of Revenue | 0.10 | % |
| Gross Profit Margin | 58.1 | % |
| EBITDA Margin | 27.1 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 61.4 | % |
| Return on Assets (ROA) | 10.2 | % |
| Return on Equity (ROE) | 18.7 | % |
| Return on Capital Invested (ROCI) | 11.9 | % |
| Current Ratio | 4.6 | |
| Leverage Ratio (Assets/Equity) | 1.8 | |
| Interest Cover | 15.8 | |
| Total Debt/Equity (Gearing Ratio) | 0.55 | |
| LT Debt/Total Capital | 35.0 | % |
| Working Capital pS | 9.03 | $ |
| Cash pS | 0.00 | $ |
| Book-Value pS | 13.78 | $ |
| Tangible Book-Value pS | 4.46 | $ |
| Cash Flow pS | 2.91 | $ |
| Free Cash Flow pS | 2.40 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 5.26 | |
| Price/Tangible Book Ratio | 0.00 | |
| Price/Cash Flow | 24.9 | |
| Price/Free Cash Flow | 30.2 | |
| P/E as % of Industry Group | 104.0 | % |
| P/E as % of Sector Segment | 84.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | Cash Payment |
| Dividend Rate | 1.40 |
| Current Dividend Yield | 1.8 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 1.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.3 | 1 | 524,340 | 2,079,703 |
| 4 Weeks | 79.63 | 71.29 | 76.99 | -5.5 | -4 | 1,023,471 | 21,492,904 |
| 13 Weeks | 79.63 | 67.61 | 68.41 | 6.4 | 5 | 693,489 | 44,383,300 |
| 26 Weeks | 79.63 | 67.04 | 72.27 | 0.7 | -3 | 642,190 | 81,558,248 |
| 52 Weeks | 79.63 | 56.59 | 70.07 | 3.9 | -7 | 741,716 | 186,912,505 |
| YTD | 79.63 | 61.22 | - | 17.5 | 10 | 683,813 | 108,726,340 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 72.92 | 73.34 | 76.13 | 72.17 | 69.19 | 0.00 | 0.00 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.09 | 0.3 | 0.10 |
| Income | 0.06 | 0.2 | 0.00 |
| Dividend | | 0.3 | 0.10 |
| Capital Spending | 0.02 | NA | 0.02 |
| R&D | 15.95 | NA | 17.11 |
| Normalized Inc. | 22.42 | NA | 17.42 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 10.4 | 9.9 | 10.1 |
| Earnings % | 31.5 | 31.4 | 12.3 |
| EPS % | 35.6 | 31.8 | 18.8 |
| EPS $ | 0.42 | 0.14 | 0.27 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 37.02 |
| Current Ratio | 4.6 |
| Quick Ratio (Acid Test) | 3.5 |
| Liquidity Ratio (Cash) | 4.56 |
| Receivables Turnover | 5.0 |
| Average Collection Period | 72 |
| Working Capital/Equity | 65.5 |
| Working Capital pS | 9.03 |
| Cash-Flow pS | 2.91 |
| Free Cash-Flow pS | 2.40 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 5.79 |
| Financial Leverage Ratio (Assets/Equity) | 0.6 |
| Debt Ratio | 31.1 |
| Total Debt/Equity (Gearing Ratio) | 0.55 |
| LT Debt/Equity | 0.55 |
| LT Debt/Capital Invested | 37.8 |
| LT Debt/Total Liabilities | 100.0 |
| Interest Cover | 15.8 |
| Interest/Capital Invested | 0.91 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 0.00 |
| Tobin's Q Ratio | 2.97 |
| Current P/E Ratio - LTM | 30.00 |
| Enterprise Value (EV)/EBITDA | 18.21 |
| Enterprise Value (EV)/Free Cash Flow | 31.36 |
| Dividend Yield | 1.8 |
| Price/Tangible Book Ratio - LTM | 0.00 |
| Price/Book Ratio - LTM | 5.26 |
| Price/Cash Flow Ratio | 24.9 |
| Price/Free Cash Flow Ratio - LTM | 30.2 |
| Price/Sales Ratio | 0.00 |
| P/E Ratio (1 month ago) - LTM | 23.9 |
| P/E Ratio (26 weeks ago) - LTM | 22.3 |
| P/E Ratio (52 weeks ago) - LTM | 20.4 |
| 5-Y High P/E Ratio | 33.2 |
| 5-Y Low P/E Ratio | 14.9 |
| 5-Y Average P/E Ratio | 22.3 |
| Current P/E Ratio as % of 5-Y Average P/E | 26 |
| P/E as % of Industry Group | 104.0 |
| P/E as % of Sector Segment | 84.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 22.4 |
| PER SHARE FIGURES |
| LT Debt pS | 7.74 |
| Current Liabilities pS | 2.58 |
| Tangible Book Value pS - LTM | 4.46 |
| Book Value pS - LTM | 13.78 |
| Capital Invested pS | 21.37 |
| Cash pS - LTM | 0.00 |
| Cash Flow pS - LTM | 2.91 |
| Free Cash Flow pS - LTM | 2.40 |
| Earnings pS (EPS) | 2.42 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 16.58 |
| Free Cash Flow Margin 5YEAR AVG | 20.61 |
| Net Profit Margin | 0.2 |
| Net Profit Margin - 5YEAR AVRG. | 0.2 |
| Equity Productivity | 1.05 |
| Return on Equity (ROE) | 0.2 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.2 |
| Capital Invested Productivity | 0.68 |
| Return on Capital Invested (ROCI) | 0.2 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 0.2 |
| Assets Productivity | 0.60 |
| Return on Assets (ROA) | 0.1 |
| Return on Assets (ROA) - 5YEAR AVRG. | 0.1 |
| Gross Profit Margin | 58.1 |
| Gross Profit Margin - 5YEAR AVRG. | 0.6 |
| EBITDA Margin - LTM | 27.1 |
| EBIT Margin - LTM | 21.6 |
| Pre-Tax Profit Margin | 0.2 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.2 |
| Effective Tax Rate | 7.0 |
| Effective Tax Rate - 5YEAR AVRG. | 12.6 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 6,127,754 |
| Revenue per Employee | 339,924 |
| Net Income per Employee | 56,297 |
| Average Collection Period | 6,127,754 |
| Receivables Turnover | 5.0 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 3.5 |
| Inventory/Sales | 13.0 |
| Accounts Payble/Sales | 4.49 |
| Assets/Revenue | 1.67 |
| Net Working Capital Turnover | 1.61 |
| Fixed Assets Turnover | 1.13 |
| Total Assets Turnover | 0.6 |
| Revenue per $ Cash | 2.51 |
| Revenue per $ Plant | 5.24 |
| Revenue per $ Common Equity | 1.05 |
| Revenue per $ Capital Invested | 0.68 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 26.8 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 1.0 |
| Research & Devlopment (R&D) as % of Revenue | 7.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 7.0 |
|
|  
| | |  |  | | |
